LIXTE Expands Ovarian Cancer Trial with MD Anderson and GSK

The clinical trial evaluating LIXTE's LB-100 compound in combination with GSK's Dostarlimab has added a second site and is expected to double enrollment.

Published on Feb. 25, 2026

Got story updates? Submit your updates here. ›

LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced an expansion of its collaboration with The University of Texas MD Anderson Cancer Center and pharmaceutical manufacturer GSK on an ongoing clinical trial evaluating its proprietary compound LB-100 in combination with GSK's Dostarlimab for the treatment of ovarian clear cell cancer. The trial has added a second site at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and is expected to double enrollment to 42 patients.

Why it matters

This expansion of the ovarian cancer trial demonstrates LIXTE's commitment to advancing its novel cancer treatment approach and the potential of the LB-100 compound to enhance existing therapies. The collaboration with a major pharmaceutical company like GSK also highlights the industry's interest in LIXTE's innovative work.

The details

The trial, initiated in January 2024 and led by Amir Jazaeri, MD, at MD Anderson, has added a second site at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University under the direction of Emily M. Hinchcliff, MD, MPH. The expanded trial is expected to double enrollment to 42 patients following completion of its initial 21-patient target. The company also expects data from the initial cohort to be presented in the first half of 2026.

  • The trial was initiated in January 2024.
  • The trial is expected to double enrollment to 42 patients.
  • Data from the initial cohort is expected to be presented in the first half of 2026.

The players

LIXTE Biotechnology Holdings, Inc.

A clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies.

The University of Texas MD Anderson Cancer Center

A comprehensive cancer center that is one of the world's most respected resources for cancer care.

GSK

A multinational pharmaceutical company that is collaborating with LIXTE on the ovarian cancer trial.

Amir Jazaeri, MD

The lead investigator of the ovarian cancer trial at MD Anderson.

Emily M. Hinchcliff, MD, MPH

The lead investigator of the ovarian cancer trial at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Got photos? Submit your photos here. ›

What’s next

The company expects data from the initial cohort of the expanded trial to be presented in the first half of 2026.

The takeaway

LIXTE's collaboration with a major pharmaceutical company like GSK and the expansion of its ovarian cancer trial highlight the industry's interest in the company's innovative approach to cancer treatment using its proprietary LB-100 compound.